Oculis Holding AG (FRA:CR5) EBITDA Margin %: 0.00% (As of Mar. 2026)


FRA:CR5 Oculis Holding AG FRA:CR5
35 GF Score
Price €11.00
! 1 Warning Sign
View Full Analysis

What is Oculis Holding AG EBITDA Margin %?

Oculis Holding AG FRA:CR5 +12.70% 35 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates FRA:CR5 with a GF Score™ of 35/100. The stock has 1 warning sign investors should review. Among 941 Biotechnology companies, Oculis Holding AG ranks worse than 106269.82% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Oculis Holding AG's EBITDA for the three months ended in Mar. 2026 was €-31.45 Mil. Oculis Holding AG's Revenue for the three months ended in Mar. 2026 was €0.00 Mil. Therefore, Oculis Holding AG's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

Oculis Holding AG  (FRA:CR5) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Oculis Holding AG EBITDA Margin % Related Terms

Oculis Holding AG EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Oculis Holding AG's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oculis Holding AG EBITDA Margin % Chart

Oculis Holding AG Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Oculis Holding AG Quarterly Data
Dec20 Sep21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:CR5 vs NVCT, AURA, CADL: EBITDA Margin % Comparison

For the Biotechnology subindustry, Oculis Holding AG's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oculis Holding AG EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oculis Holding AG's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Oculis Holding AG's EBITDA Margin % falls into.


FRA:CR5
35GF Score
Oculis Holding AG FRA:CR5
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oculis Holding AG EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Oculis Holding AG's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-104.769/0
= %

Oculis Holding AG's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-31.448/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Oculis Holding AG (FRA:CR5) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Oculis Holding AG and its competitors. According to the industry distribution chart, Oculis Holding AG ranks #999999 out of 941 companies in the Biotechnology industry.
Is Oculis Holding AG's EBITDA Margin % too high?
Oculis Holding AG's current EBITDA Margin % is 0.00%. Based on the distribution chart, Oculis Holding AG ranks #999999 out of 941 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oculis Holding AG has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Oculis Holding AG's EBITDA Margin % compare to NVCT and AURA?
According to the Biotechnology industry distribution chart, Oculis Holding AG ranks #999999 out of 941 companies for EBITDA Margin %. This places Oculis Holding AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Oculis Holding AG and its competitors. Oculis Holding AG's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oculis Holding AG stock overvalued right now?
Oculis Holding AG (FRA:CR5) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Oculis Holding AG's overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Oculis Holding AG (FRA:CR5), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oculis Holding AG Business Description

Address Bahnhofstrasse 20, Zug, CHE, CH-6300
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
35GF Score

Get the complete analysis for FRA:CR5

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.00
Price